Exelixis Inc
EXEL
ISIN null / Valor 1069927
Exelixis Inc
UMushroom community rating:
About company
Exelixis Inc. is a biotechnology company primarily engaged in the discovery, development, and commercialization of new medicines to treat cancer. Initially founded with a focus on using model systems genetics and genomics to understand gene function, the company has since honed its expertise in drug discovery. Exelixis is known for its development of small molecule therapies, with a particular emphasis on oncology. The company has established a robust pipeline of drug candidates and has successfully brought several products to market. Exelixis leverages strategic collaborations with other pharmaceutical and biotechnology companies to enhance its research and development efforts, thereby expanding its reach and impact in the field of cancer treatment.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (14.11.2025):
Exelixis Inc reported strong financial results for the first quarter of 2025, with total revenues of $555.4 million and U.S. cabozantinib franchise net product revenues of $513.3 million, marking significant growth over the previous year. The quarter also saw GAAP diluted EPS at $0.55 and non-GAAP diluted EPS at $0.62, alongside an update to its full year 2025 guidance—increasing both net product and total revenues by $100 million. The report highlighted robust operational performance, key product launches, and strategic pipeline developments.
Revenue Growth
Total revenues increased to $555.4 million in Q1 2025 compared to $425.2 million in Q1 2024, driven primarily by a rise in sales volume and an improved average net selling price for cabozantinib products.
Earnings Performance
Exelixis Inc reported GAAP diluted EPS of $0.55 and non-GAAP diluted EPS of $0.62, reflecting a sizable improvement from the previous year, underpinned by enhanced net income and effective cost management.
Guidance Update
Based on strong first quarter dynamics, the company increased its full year 2025 guidance by $100 million for both total and net product revenues, signaling high confidence in sustained growth for the remainder of the year.
Pipeline and Launch Highlights
In addition to strong earnings, Exelixis received FDA approval for CABOMETYX in advanced neuroendocrine tumors and is actively progressing key clinical trials and pipeline milestones, including pivotal trial updates for zanzalintinib that reinforce its multi-franchise oncology strategy.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
12398 M
Market cap (USD)
1,537,799
Daily traded volume (Shares)
34.14 / 33.69
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
